Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

VDOT for Monitoring Adherence to LTBI Treatment (VMALT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02641106
Recruitment Status : Recruiting
First Posted : December 29, 2015
Last Update Posted : October 11, 2018
Sponsor:
Information provided by (Responsible Party):
Richard Garfein, University of California, San Diego

Brief Summary:
The three-month short-course treatment with isoniazid [H] and rifapentine [P] (3HP) recently recommended by the Centers for Disease Control and Prevention could dramatically increase the number of persons starting and completing treatment for latent tuberculosis infection (LTBI), but TB providers nationwide are hamstrung by the requirement that 3HP only be administered by directly observed therapy (DOT) in which patients are watched taking each medication dose in-person. We developed a novel mHealth application that allows patients to make and send videos of each medication dose ingested that are watched by healthcare providers via a HIPAA-compliant website to remotely monitor LTBI treatment adherence (Video DOT [VDOT]). This study will determine whether monitoring patients with VDOT achieves higher treatment completion rates and greater patient acceptability at lower cost than clinic-based in-person DOT.

Condition or disease Intervention/treatment Phase
Tuberculosis Latent Tuberculosis Infection Other: Video Directly Observed Therapy Other: In-Person DOT Not Applicable

Detailed Description:

Building on our novel VDOT System that includes text messaging reminders and HIPAA-compliant cloud-based administration, we hypothesize that VDOT can be expanded to provide higher treatment completion rates at a lower cost than in-person DOT for LTBI treatment using 3HP. We propose a randomized controlled trial to address the following specific aims:

Aim 1: To determine whether LTBI treatment completion and adherence are greater for patients treated with 3HP administered via VDOT versus in-person DOT, and to identify patient factors associated with these outcomes; Aim 2: To compare acceptability of treatment by patients on VDOT versus in-person DOT, and identify factors associated with differences in acceptability; Aim 3: To calculate the cost-effectiveness of VDOT compared to in-person DOT for administering 3HP.

To address the study aims we will conduct a randomized controlled trial in which TB contacts and refugees in San Diego who are prescribed 3HP for LTBI treatment by their physician will be randomly assigned to be monitored for adherence via either VDOT or in-person DOT (Figure 2). Approximately 100 patients per year over three years (n=155/arm) will be recruited through the San Diego County TB Control and Refugee Health Program (TCRHP) clinics for the trial. Patients assigned to VDOT will be given a smartphone with service and taught to send videos of themselves taking each weekly medication dose; patients in the in-person DOT arm will visit the clinic each week to be observed by a healthcare worker taking their LTBI medication. Medication adherence will be monitored for all participants until they have taken all 12 doses or 16 weeks (limit recommended by the CDC to complete treatment), to compare treatment adherence rates and patient acceptance across trial arms. Participants will complete brief (20 minute) baseline and follow-up assessment interviews to obtain information about potential confounders and effect modifiers of adherence and patient acceptance regarding their treatment administration method. Cost-benefit analyses will also be conducted to assist in developing policies around the use of VDOT for 3HP. Since participants will be recruited after they have been prescribed 3HP by their healthcare provider and all patient care will be continued through their provider, no medications will be prescribed or treatment decisions made this study.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 310 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Video Directly Observed Therapy (VDOT) to Monitor Short-Course LTBI Treatment
Actual Study Start Date : March 8, 2016
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tuberculosis

Arm Intervention/treatment
Experimental: Video Directly Observed Therapy
VDOT arm participants use a smartphone to make a video recording of each weekly medication dose ingested using the VDOT mobile phone app. The VDOT app is programmed to send encrypted, time/date stamped videos to a HIPAA-compliant server as soon as the video recorder is stopped. Clinic staff monitor videos as they arrive using a password protected website and document each medication dose that is taken. Dose 1 is observed in-person; doses 2-12 are observed via videos.
Other: Video Directly Observed Therapy
Video Directly Observed Therapy (VDOT) is a novel means of remotely observing patients ingesting medications using videos sent from a smartphone. VDOT was developed and found to be feasible and acceptable for monitoring daily treatment of active TB in San Diego, CA and Tijuana, B.C., Mexico (R21-AI088326; PI: R. Garfein). Patients are taught how to use the VDOT recording app, record medication ingestion, and contact their physician when side effects occur. Participants are trained at the time of their first LTBI treatment dose to ensure participants know how to record videos. All remaining 11 weekly doses are taken and recorded wherever the participant chooses. Clinic staff monitor videos as they arrive using a password protected website and document each medication dose that is taken.
Other Name: VDOT

Active Comparator: In-Person DOT
In-Person DOT arm participants follow standard-of-care procedures for monitoring ingestion of all medication doses. Participants take their first medication dose at the enrollment visit and return to the clinic once weekly to be observed taking the remaining 11 doses of medication until they complete the 12-dose regimen.
Other: In-Person DOT
Clinic-based, in-person DOT is the standard of care for monitoring adherence for patients taking the 12-dose isoniazid/rifapentine treatment for LTBI. Participants visit the clinic once weekly until all 12 doses are taken or 16 weeks pass, whichever comes first.
Other Name: Control




Primary Outcome Measures :
  1. Proportion of participants completing LTBI treatment [ Time Frame: 16 weeks ]
    The proportion of participants completing treatment (i.e., taking all 12 prescribed doses within 16 weeks). At the end of 16 weeks, the participant will have either completed the 12-dose treatment or considered defaulted.

  2. Participant satisfaction with method of monitoring LTBI treatment [ Time Frame: 16 weeks ]
    Compare level of participant satisfaction with treatment by each method of treatment monitoring. After the last dose of medication is taken (or at 16 weeks for those who do not complete treatment), follow-up interviews will collect treatment satisfaction outcome data.

  3. cost-effectiveness of VDOT compared to in-person DOT for administering 3HP [ Time Frame: 4 years ]
    Compare the cost of providing DOT by each method of treatment monitoring. Since this outcome requires program costs for delivery of the VDOT intervention, the time frame for collecting all cost data is 4 years.


Secondary Outcome Measures :
  1. Proportion of participants completing LTBI treatment in 12 weeks [ Time Frame: 12 weeks ]
    Proportion of participants completing LTBI treatment on-schedule (i.e., participants took all 12 doses within 12 weeks, as prescribed). By the end of 12 weeks, participants who ingested 12 doses within 12 weeks will be counted as achieving this outcome; all others will be counted failing this outcome.

  2. Proportion of participants who took all 12 LTBI treatment doses on-schedule [ Time Frame: 12 weeks ]
    Proportion of participants completing LTBI treatment on-schedule (i.e., participants took all 12 doses on the same day each week for 12 consecutive, as prescribed). By the end of 12 weeks, participants who ingested 12 doses within 12 weeks on the same day each week will be counted as achieving this outcome; all others will be counted failing this outcome.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   13 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Diagnosis of LTBI and patient's physician determines that they are eligible to receive 3HP
  2. Age ≥13 years;
  3. No plans to move out of the San Diego area within 4 months of enrollment; and
  4. Willing to comply with study procedures and provide informed consent (or assent for minors and parental consent) prior to study enrollment.

Exclusion Criteria:

  1. Are younger than 13 years old;
  2. Plan to move out of San Diego County within 4 months of enrollment;
  3. Refuse to allow study staff to review their medical records;
  4. Are incarcerated;
  5. Have a physical (e.g., blindness) or cognitive disabilities that make VDOT impractical unless someone else in their household can assist them for the duration of the study; or
  6. Are using other medications that preclude the use of 3HP (e.g., antiretroviral medication for HIV).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02641106


Contacts
Layout table for location contacts
Contact: Richard S Garfein, PhD, MPH 858-822-3018 rgarfein@ucsd.edu
Contact: Jazmine Cuevas-Mota, MPH 619-767-9602 jcuevasmota@ucsd.edu

Locations
Layout table for location information
United States, California
San Diego County Health and Human Services Agency Recruiting
San Diego, California, United States, 92110
Contact: Wilma J Wooten, M.D., M.P.H    619-515-6597    Wilma.Wooten@sdcounty.ca.gov   
Contact: Antonette Antonio, NP, RN    619-692-5718    Antonette.Antonio@sdcounty.ca.gov   
Sponsors and Collaborators
University of California, San Diego
Investigators
Layout table for investigator information
Principal Investigator: Richard S Garfein, PhD, MPH University of California, San Diego

Layout table for additonal information
Responsible Party: Richard Garfein, Professor, University of California, San Diego
ClinicalTrials.gov Identifier: NCT02641106     History of Changes
Other Study ID Numbers: 150155
First Posted: December 29, 2015    Key Record Dates
Last Update Posted: October 11, 2018
Last Verified: October 2018
Keywords provided by Richard Garfein, University of California, San Diego:
Telemedicine
Mobile Phone
Adherence
Latent Tuberculosis Infection
Directly Observed Therapy
Video DOT
Additional relevant MeSH terms:
Layout table for MeSH terms
Tuberculosis
Latent Tuberculosis
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections